<DOC>
	<DOCNO>NCT00526097</DOCNO>
	<brief_summary>The objective study compare efficacy safety 4 week treatment bisacodyl ( Dulcolax ) tablets 10 mg placebo patient functional constipation . In addition , effect treatment quality life general health status evaluate .</brief_summary>
	<brief_title>Dulcolax v Placebo Functional Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Bisacodyl</mesh_term>
	<criteria>1 . Male female patient , age 18 2 . Suffering functional constipation , accord medical history , define Rome III diagnostic criterion , i.e . : Criteria fulfil last 3 month symptom onset least 6 month prior diagnosis . 1 . Must include 2 follow : : straining least 25 % defecation lumpy hard stool least 25 % defecation sensation incomplete evacuation least 25 % defecation sensation anorectal obstruction/blockade least 25 % defecation manual manoeuvre facilitate least 25 % defecation ( e.g . digital evacuation , support pelvic floor ) few 3 defecation per week 2 . Loose stool rarely present without use laxatives 3 . There insufficient criterion irritable bowel syndrome ( IBS ) 3 . Able willing complete daily ediary 4 . Able willing use trial rescue medication 5 . Signed date write informed consent prior enrolment study accordance GCP local legislation At Visit 2 , patient must comply follow additional inclusion criterion eligible entry treatment phase : 6 . Functional constipation confirm ediary data end baseline period : . An average less 3 CSBMs per week , together least one follow symptom occur least 25 % time : strain incomplete evacuation lumpy hard stool ( i.e . type 1 type 2 stool ) 7 . Compliant use ediary throughout baseline period ( compliance define complete 80 % evening report ) 8 . Compliant use rescue medication throughout baseline period . Compliance define follow : rescue medication may use bowel movement 72 hr rescue medication may use either day 1 day randomisation ( day 1 ) 1 . Eating disorder anorexia nervosa bulimia , cause excessive use laxatives 2 . Patients whose constipation cause primary organic disease colon pelvic floor 3 . Patients metabolic disorder , neurological disorder , severe psychiatric disorder , significant disease intercurrent illness ( e.g . abdominal/gastrointestinal surgery ) , Investigators opinion , would interfere participation trial 4 . Patients restricted mobility ( e.g . wheelchair bound , bedridden ) , Investigators opinion , would interfere participation trial 5 . Patients know hypersensitivity bisacodyl ingredient study medication 6 . Patients ileus , intestinal obstruction , acute surgical abdominal condition ( acute appendicitis acute inflammatory bowel disease ) , severe dehydration 7 . Patients anal fissure ulcerative proctitis mucosal damage 8 . Patients know clinically significant abnormal electrolyte value 9 . Patients whose concomitant therapy include opioid medication ( e.g . morphine , codeine ) 10 . Constipation , Investigators opinion , cause medication ( e.g . anticholinergic ) 11 . Patients willing discontinue use prohibit concomitant therapy 12 . Premenopausal woman : 1. nursing ( breastfeed ) pregnant OR 2. childbearing potential practicing acceptable method birth control , plan continue use method throughout study . Acceptable method birth control include : transdermal patch intrauterine devices/systems ( IUDs/IUSs ) oral , implantable injectable contraceptive sexual abstinence sterilisation vasectomise partner 13 . Participation another trial investigational product 1 month enrolment study 14 . Drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>